Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -226.71M | -321.55M | -351.45M | -145.91M | -161.13M |
| Total Depreciation and Amortization | 46.48M | 43.56M | 40.95M | 41.19M | 41.79M |
| Total Amortization of Deferred Charges | 1.73M | 1.73M | 1.72M | 1.72M | 1.72M |
| Total Other Non-Cash Items | 101.61M | 101.81M | 99.88M | -124.38M | -192.95M |
| Change in Net Operating Assets | -83.77M | -63.02M | -63.32M | -61.48M | -7.34M |
| Cash from Operations | -160.66M | -237.48M | -272.23M | -288.86M | -317.91M |
| Capital Expenditure | 0.00 | 0.00 | 561.00K | 551.00K | 630.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.72M | 99.33M | 162.12M | 249.33M | 197.08M |
| Cash from Investing | 35.72M | 99.33M | 162.68M | 249.88M | 197.71M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 145.77M | 141.52M | 2.79M | 2.37M | 4.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.10M | -2.10M | -2.36M | -2.62M | -2.88M |
| Cash from Financing | 143.67M | 139.42M | 427.00K | -253.00K | 1.23M |
| Foreign Exchange rate Adjustments | -72.00K | -913.00K | 1.28M | 649.00K | 840.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.65M | 359.00K | -107.84M | -38.58M | -118.13M |